Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
rose from 5.4% in 2020 to 6.6% in 2023, alongside advancing its lead candidate DT120 ODT, which has FDA Breakthrough Therapy Designation for GAD and is approaching potential commercialization. This combination of rising GAD burden and regulatory recognition for DT120 ODT underscores how Definium is positioning its psychedelic-based therapy portfolio toward large, underserved psychiatric needs. We'll now explore how FDA Breakthrough Therapy Designation for DT120 ODT may reshape Definium Therapeutics' investment narrative and future expectations. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it . Find the list for free. Definium Therapeutics Investment Narrative Recap To own Definium Therapeutics, you need to believe DT120 ODT can convert its FDA Breakthrough Therapy Designation and late stage program into an approved treatment for large GAD and MDD populations, before cash needs become too
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]Yahoo! Finance
- Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]Seeking Alpha
- Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.MarketBeat
- Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- DFTX's page on the SEC website